ClinicalTrials.gg
Enrolling by invitationNCT05981872Updated Aug 8, 2023

EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19

An interventional study of rehacom in Post-COVID-19 Syndrome, sponsored by Cairo University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 months after the study started (first participant enrolled May 2023, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test the effect of Rehacom on depression and Quality of life in post covid -19 patients. The main question it aims to answer is:

  • Is a cognitive rehabilitation therapy will improve depression and quality of life in patients with post COVID-19? Researchers will compare Rehacom with exercise therapy to see if rehacom can improve depression and quality of life in patients with post COVID-19 neuropsychological problems.
Read the detailed description

Purpose of the study:

  • To investigate the effect of cognitive rehabilitation therapy on depression in post COVID-19 patients.
  • To investigate the effect of cognitive rehabilitation therapy on quality of life in post COVID-19 patients.

Significance of the study:

•There is growing evidence that individuals with COVID-19 disease can develop a range of neurological complications including cognitive and neuropsychiatric symptoms . Cognitive rehabilitation essential in improving quality of life with Introduction of new neuropsychological rehabilitation tools based on the latest developments in computer sciences.

This study aims to investigate the RehaCom as a cognitive rehabilitation program on depression and quality of life in patients suffer from post COVID-19 neuropsychological problems.

02

Conditions studied

  • Post-COVID-19 Syndrome

Keywords

  • Rehacom
  • post covid-19
  • cognitive rehabilitation
  • depression
  • Quality of life
03

In context

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 36 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients will be selected according to following criteria:

    1. Patients from both genders (male and female).
    2. The age of participants ranged from 30 to 45 years .
    3. The patients had score more than 24 according to (MMSE).
    4. Patient muscle power not less than grade 3 .
    5. Patients are ambulant.
    6. Patients with confirmation of previous covid19 infection PCR TEST.
    7. Participants were required to live in Egypt during the pre-covid and COVID-19 pandemic.
    8. Patients meeting the guide line of world health organization (WHO) of long/post-covid 19 syndromes.
    9. Patients are "long-haulers" those who history of probable or confirmed SARS-CoV-2 infection; usually within three months from the onset of COVID-19, and last more than two months

Exclusion criteria

Exclusion Criteria:

  • The patients will be excluded if they have any of the following:

    1. Patient previously diagnosed with depression and currently taking medication.
    2. patient had prior cognitive impairment.
    3. Illiterate patients.
    4. patient had experienced another major stressful event (e.g., divorce, bereavement) in the past year.
    5. Checking comorbidities (sum of hypertension, diabetes, arrhythmia, myocardial infarction, /Asthma.
    6. Mild cognitive impairment, dementia, other neurodegenerative diseases, stroke, depression,
    7. Osteoarthritis , low back pain and prevalence of polypharmacy (5 or more drugs) at admission.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    post covid-19 patients with neurological symptoms as study group

    •Study group (A) will receive cognitive rehabilitation (Rehacom ) for 30 minutes and selected physical therapy program(that included aerobic, strength, and balance training for 30 minutes, with total duration 60 minutes. 3 sessions per week for 12 weeks.

    Behavioral: rehacom

  • Active comparator
    post covid-19 patients with neurological symptoms as control group

    Control group (B) which will include 18 patients who will receive only selected physical therapy program (that included aerobic, strength, and balance training ). The treatment will conducted for 60 minutes, 3 sessions per week for 12 weeks

    Behavioral: rehacom

Interventions

  • Behavioralrehacom

    Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration. 1. Attention concentration training consists of 24 levels of difficulties . 2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty.

    Also known as: cognitive behavioral therapy

06

What researchers measure

Primary outcomes

  1. The Mini- Mental State Examination (MMSE)

    The Mini- Mental State Examination (MMSE) was designed to provide a standardized, brief and practical assessment of cognitive status in geriatric patients. It is used as a brief screening tool for cognitive impairment and does not identify specific disorders. It concentrates only on the cognitive aspects of mental functions and excludes questions on mood, abnormal mental experiences as well as the form of thinking.

    Time frame: The MMSE is easily administered and requires only 5-10 minutes to complete depending on the impairment of the individual

  2. Beck depression inventory (BDI)

    • The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). Anxiety symptoms are not assessed but affective, cognitive, somatic, and vegetative symptoms are covered, reflecting the DSM-IV criteria for major depression. Scoring is achieved by adding the highest ratings for all 21 items. The minimum score is 0 and maximum score is 63. Higher scores indicate greater symptom severity.

    Time frame: easily administered and requires only 5-10 minutes to complete depending on the impairment of the individual

  3. .Katz Index of Independence in Activities of Daily Living

    Katz ADL is the most appropriate instrument to assess functional status as a measurement of the client's ability to perform activities of daily living independently. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding.

    Time frame: easily administered and requires only 5-10 minutes to complete depending on the impairment of the individual

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Sep 2023, 4 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2023
First posted
Aug 8, 2023
StartActual
May 4, 2023
Primary completionEst.
Sep 2023
CompletionEst.
Jan 2024
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05981872
Lead sponsor
Cairo University
Responsible party
Allaa Ashraf Maher Mohammed Elfwey (physical therapist, Cairo University) — Principal investigator
First posted
Aug 8, 2023
Start date
May 4, 2023
Primary completion
Sep 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Aug 8, 2023

Study contacts

Hossam M Mohammed, PHD
principal investigator · Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion